Megan C. Turner

Megan C. Turner

Auto-generated profile, based on publicly available information

Megan C. Turner

Duke University Medical Center

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2019 in Clinics in Colon and Rectal Surgery
Verified
Journal Article
Closed access
PDF file
MTMegan C. Turner
Megan C. Turner
JMJohn Migaly
John Migaly
Surgical site infection (SSI) following colorectal surgery is associated with worse postoperative outcomes, longer length of stay, and higher rates of readmission. SSI rates have been established as a surrogate metric for the overall quality of surgical care and are intricately tied to financial incentives and the public reputation of an institution. While risk factors and prevention mechanisms for SSI are well established, the rates of SSI remain high. This article discusses the clinical and economic impact of SSI and strategies for mitigating the risk of SSI through bundled prevention practices.

1 April 2018 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
MTMegan C. Turner
Megan C. Turner
NFNorma E. Farrow
Norma E. Farrow
KRKristen E. Rhodin
Kristen E. Rhodin
ZSZhifei Sun
Zhifei Sun
MAMohamed A. Adam
Mohamed A. Adam
JMJohn Migaly
John Migaly
Adjuvant chemotherapy after resection is the standard of care for stage III colon cancer, yet many patients omit chemotherapy. We aimed to describe the impact of delayed chemotherapy on overall survival across multiple time points. The 2006 to 2014 National Cancer Data Base (NCDB) was queried for patients with single primary stage III adenocarcinoma of the colon. Patients were grouped by receipt and timing of chemotherapy from resection date: chemotherapy omitted, 24 weeks. Subgroup analyses were performed for those with comorbidities and those who had postoperative complications. Overall survival was compared using Cox proportional hazard modeling, adjusting for patient, tumor, and facility characteristics. In total, 72,057 patients were included; 20,807 omitted chemotherapy, 22,705 received it at 24 weeks after resection. Compared with patients who omitted chemotherapy, patients who received chemotherapy at 24 weeks (HR 0.68) had superior overall survival (p < 0.001). This survival benefit was preserved across subgroups (p < 0.001). After resection of stage III colon cancer, patients should receive adjuvant chemotherapy within 6 to 8 weeks for maximal benefit. However, chemotherapy should be offered to patients who are outside the optimal window, who have significant comorbidities, or who have had a complication more than 24 weeks from resection to improve the overall survival compared with omitting chemotherapy.

11 January 2019 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
MTMegan C. Turner
Megan C. Turner
JKJeffrey E. Keenan
Jeffrey E. Keenan
CRChristel N. Rushing
Christel N. Rushing
BGBrian C. Gulack
Brian C. Gulack
DNDaniel P. Nussbaum
Daniel P. Nussbaum
JMJohn Migaly
John Migaly

12 June 2019 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
MTM. C. Turner
M. C. Turner
DBD. Becerra
D. Becerra
ZSZ. Sun
Z. Sun
JWJ. Watson
J. Watson
KLK. Leung
K. Leung
DBD. G. Blazer
D. G. Blazer

23 September 2017 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
SAShaunak S. Adkar
Shaunak S. Adkar
MTMegan C. Turner
Megan C. Turner
HLHarold J. Leraas
Harold J. Leraas
BGBrian F. Gilmore
Brian F. Gilmore
UNUttara Nag
Uttara Nag
LMLeila Mureebe
Leila Mureebe

1 April 2022 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
MTMegan C. Turley
Megan C. Turley
CMCarrie Moore
Carrie Moore
JCJohn M. Creasy
John M. Creasy
JSJeremy Sharib
Jeremy Sharib
BLBilly Lan
Billy Lan
MLMichael E. Lidsky
Michael E. Lidsky